BPN-14770 is a novel compound currently under investigation for the treatment of Alzheimer’s disease and age-related cognitive decline. It works by targeting a specific enzyme pathway involved in memory and learning.
How It Works
BPN-14770 is a negative allosteric modulator of the PDE4 enzyme, with high selectivity for the PDE4D isoform. This enzyme is involved in the breakdown of cAMP, a key messenger molecule in the brain linked to:
-
Memory formation
-
Synaptic plasticity
-
Mood and motivation
By selectively modulating PDE4D, BPN-14770 aims to enhance cognitive function without the nausea often associated with non-selective PDE4 inhibitors.
Dosing Strategy
⚠️ Due to its investigational status and limited long-term safety data, BPN-14770 should be used conservatively and only for research purposes.
| Level | Total Daily Dose |
|---|---|
| Beginner | 2.5–5 mg/day (can split dosing due to 10-hour half-life) |
| Intermediate | 5–15 mg/day |
| Advanced | 20 mg/day or more (higher doses should be approached with caution) |
Pharmacokinetics
-
Half-life: ~10 hours
-
May be redosed later in the day for smoother cognitive effects, especially at lower doses.